AHA26: Orforglipron outpaces oral semaglutide on predicted cardiovascular risk
GlobalData expects Eli Lilly to pair this CV risk data with orforglipron’s dosing convenience to differentiate it from oral semaglutide.
The post AHA26: Orforglipron outpaces oral semaglutide on predicted cardiovascular risk appeared first on Clinical Trials Arena .